CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer

Affiliations

¹ Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan 20141, Italy. Electronic address: antonio.passaro@ieo.it.
² Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan 20141, Italy.

Comment

Antonio Passaro et al. Lancet Oncol. 2021 Feb.

. 2021 Feb;22(2):157-159.

doi: 10.1016/S1470-2045(20)30701-4. Epub 2021 Jan 18.

¹ Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan 20141, Italy. Electronic address: antonio.passaro@ieo.it.
² Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan 20141, Italy.

No abstract available

Comment on

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M. Paz-Ares L, et al. Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18. Lancet Oncol. 2021. PMID: 33476593 Clinical Trial.